Edesa Biotech, Inc. reported financial results for the three months ended December 31, 2025, with total operating expenses of $2.3 million, net loss of $2.2 million or $0.28 per common share, cash and cash equivalents of $12.1 million, and working capital of $12.0 million. The company progressed EB06 manufacturing for a Phase 2 vitiligo study starting midyear 2026 and is evaluating paridiprubart Phase 3 data.
Key takeaways
Net loss of $2.2 million or $0.28 per common share for three months ended December 31, 2025 vs. $1.6 million or $0.48 per share in prior year
Total operating expenses increased $0.4 million to $2.3 million from $1.9 million year-over-year
Research and development expenses $1.1 million, up $0.1 million due to EB06 manufacturing and vitiligo study preparations
General and administrative expenses $1.2 million, up $0.3 million due to noncash share-based compensation
Cash and cash equivalents $12.1 million and working capital $12.0 million at December 31, 2025
EB06 Phase 2 vitiligo study recruitment to begin midyear 2026 subject to regulatory approvals